QR Pharma, Inc. is a clinical-stage specialty pharmaceutical company committed to developing therapeutics with novel approaches to the treatment of cognitive impairment in neurological disorders. QR has successfully completed animal studies in Alzheimer's and Parkinson's disease models; is expanding the drugs application to Huntington's, glaucoma and traumatic brain injury, was awarded $3 M from the US Army to work in Traumatic Brain Injury (TBI); and has recently been chosen by the NIH for a human phase 2 clinical trial in Alzheimer's patients.
